Controlled evidence is thin and the chorea trials were disappointing — the National Academies grade evidence as insufficient for motor outcomes. The certification rationale mirrors other neurodegenerative diseases: sleep disruption, anxiety and irritability, weight loss (caloric demands in HD are enormous), and pain. THC's appetite effect has a genuine role in a disease where weight maintenance correlates with better outcomes.
Family and caregiver logistics dominate practically: caregiver registration handles purchasing as the disease progresses, psychiatric medications common in HD (antipsychotics, SSRIs) warrant interaction review, and the cognitive dimension means starting doses stay minimal with effects tracked by someone other than the patient.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.